Abrocitinib
Catalog No.
BA4893
Abrocitinib (PF-04965842) is a potent, orally available, selective inhibitor.
Featured Products
Abrocitinib (CAS No.: 1622902-68-4) is an orally administered, highly selective Janus kinase 1 (JAK1) inhibitor, primarily used for the treatment of moderate-to-severe atopic dermatitis (AD). By inhibiting the JAK1 signaling pathway, it modulates cytokines associated with the pathogenesis of AD, such as IL-4, IL-13, and IL-31, thereby alleviating inflammatory responses and pruritus symptoms. In vitro studies show that Abrocitinib inhibits JAK1 at the nanomolar level, with selectivity over JAK2 and TYK2 of up to 28-fold and more than 340-fold, respectively. In cellular and animal models, Abrocitinib significantly reduces inflammatory responses by inhibiting relevant signaling pathways. In clinical studies, it is commonly administered orally once daily, with the dose and treatment duration typically determined according to the specific experimental design and research objectives.
| Physical Appearance | A solid |
| Storage | -20°C |
| M.Wt | 323.41 |
| Cas No. | 1622902-68-4 |
| Formula | C14H21N5O2S |
| Synonyms | PF-04965842 |
| Chemical Name | N-((1s,3s)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide |
| SDF | Download SDF |
| Canonical SMILES | N(C)(C1=C2C(NC=C2)=NC=N1)[C@H]3C[C@@H](NS(CCC)(=O)=O)C3 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |